RxDoctor Payments Data

Christopher Johnson, MD

Urology · San Luis Obispo, CANPI 1770562712

Payments from drug & device makers

$18,700in general payments, 2019–2025

Across 596 payments — averaging $31.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$2K
  • Ferring Pharmaceuticals Inc.$2K
  • Sumitomo Pharma America, Inc.$1K
  • Neotract Inc.$1K
  • Dendreon Pharmaceuticals LLC$1K
  • Johnson & Johnson$1K
  • plus $10K from 40 others

What the payments were for

  • Consulting fees$3,13617%
  • Travel & lodging$7824%
  • Food & beverage$14,62778%
  • Education$1551%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,700 in reported general payments places this provider in the 80th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$1,576,249
Medicare patients
2,281
Services billed
57,918

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide88$1,187,101
MyrbetriqMirabegron353$397,095
OrgovyxRelugolix71$184,197
GemtesaVibegron79$90,722
Abiraterone Acetate49$33,361
Tamsulosin Hcl1,195$24,560
Mirabegron ErMirabegron21$14,593
Solifenacin Succinate143$10,831
Testosterone54$10,715
Potassium Citrate ErPotassium Citrate99$10,347
Finasteride501$7,907
Methenamine Hippurate104$7,590
Dutasteride216$7,470
RenacidinCitric Ac/Gluconolact/Mag Carb24$7,129
Estradiol101$6,062

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$993$1,584,196441 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$1,272$274,919150 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,324 urology providers in California.

Other urology in San Luis Obispo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →